Microscopy image of exosomes
Exosomes, stem cell therapies, and hair cloning represent genuinely interesting science. None of them are established treatments — and several are being offered to patients at premium prices before the evidence exists to justify it.

Every few years, a new wave of regenerative treatments arrives in hair restoration clinics promising to move beyond the drugs that have dominated the field for decades. The current wave is exosomes. Before that it was stem cell therapies and, perennially, “hair cloning.” On TikTok and Reddit, a parallel stream of viral DIY remedies — onion juice, pumpkin seed oil — claims to achieve similar results with ingredients from the kitchen.

These are not the same category of claim, but they share a common feature: they are being presented to consumers with far more confidence than the clinical evidence supports. This article reviews the science and the evidence gap across all of them.

Part of a Series

This article is part of our Hair Loss: Marketing or Science? series, examining the evidence behind popular treatments and ingredients.

Exosome Scalp Therapy: Early Science, Regulatory Concern

Exosomes are nanoscale vesicles secreted by cells that carry proteins, lipids, and RNA between cells — a mechanism of intercellular communication. The interest in exosomes for hair loss centers on the observation that mesenchymal stem cell (MSC)-derived exosomes can promote hair follicle activity in preclinical models, likely by delivering growth factors and signaling molecules that support the anagen phase.

A 2025 systematic review of stem cell-derived exosomes in hair regeneration and a scoping review of exosome delivery for hair loss both describe promising preclinical and early clinical signals. A 2024 prospective study of exosome treatment in androgenetic alopecia reported measurable improvements. But the field is characterized by small studies, inconsistent exosome sources and preparations, absent standardization, and no large randomized controlled trials. A 2025 review of regenerative therapies for androgenetic alopecia explicitly lists exosomes among the “promises and pitfalls” — real mechanistic rationale, real early signal, not yet an established treatment.

The regulatory picture adds a critical layer. The FDA has issued warnings about unapproved exosome products sold for clinical use. Exosome preparations marketed as treatments are classified as biologics requiring FDA approval — approval that virtually none currently hold. Patients paying $1,500–$3,000 for scalp exosome injections are receiving an experimental, largely unregulated intervention with no standardized product, no established dosing, and limited long-term safety data.

The Claim

“Exosome therapy is the next generation of hair restoration — clinics offering it are on the cutting edge of science. Stem cell and hair cloning treatments are just around the corner. Onion juice and pumpkin seed oil have clinical studies proving they work for hair loss.”

(Composite; reflects claims across regenerative medicine clinic marketing, hair-loss forum discourse, and natural remedy content.)

Stem Cells and Hair Cloning: Perpetually Around the Corner

The concept behind hair cloning is straightforward: take dermal papilla cells from an existing follicle, multiply them in culture, and re-inject them to generate new follicles — essentially creating an unlimited supply of hair-producing cells from a small donor sample. The promise has been discussed in the literature since at least the 1990s.

Progress has been genuine but slow. A 2023 literature review of stem cell applications in hair growth describes multiple approaches — dermal papilla cell multiplication, induced pluripotent stem cells, adipose-derived stem cells — all at various stages of preclinical or early clinical investigation. Companies including Stemson Therapeutics have pursued follicle neogenesis approaches with significant investment. None have produced an approved, commercially available treatment.

The challenge is not just scientific. Cultured dermal papilla cells lose their inductive capacity over passaging — they stop being able to generate follicles when grown in standard 2D culture. Solving that problem at scale, at a cost accessible to patients, while meeting regulatory requirements for a cell therapy, is an unsolved engineering and commercial problem. “Three to five years away” has been the answer for over two decades; the timeline has not meaningfully shortened.

Viral DIY: The Onion Juice and Pumpkin Seed Oil Problem

Two natural remedies circulate persistently in hair-loss spaces with attached study citations that seem to legitimize them. Both deserve a careful read.

Onion juice owes its reputation to a single 2002 controlled study in alopecia areata patients that reported 86.9% hair regrowth with crude onion juice applied twice daily vs. tap water. The number is striking — but the study enrolled only 38 patients (23 onion juice, 15 control), and roughly half dropped out before completion. The study was in alopecia areata, an autoimmune condition, not androgenetic alopecia, so the result does not transfer to the more common pattern hair loss most people are treating. It has never been replicated. No study has compared onion juice to minoxidil.

Pumpkin seed oil rests on a single 2014 randomized, double-blind, placebo-controlled trial in men with androgenetic alopecia that found 400 mg/day oral pumpkin seed oil produced a 40% increase in hair count vs. 10% in the placebo group at 24 weeks. This is better-designed than the onion juice study — but it is a single, small trial (76 men), with a proposed mechanism (5AR inhibition via phytosterols) not confirmed by direct measurement, and no replication or head-to-head comparison with standard treatments. A single positive small trial is a reason to run more studies, not a reason to declare a treatment established.

Treatment Evidence Stage Largest RCT Compared to Minoxidil? Regulatory Status
Exosome scalp therapy Preclinical + small prospective studies None (no large RCT) No Unapproved biologic (FDA concern)
Stem cell / hair cloning Preclinical; early-phase trials None (no approved therapy) No Not approved anywhere
Onion juice One small, unreplicated trial (alopecia areata only) n=38 (2002) No No regulatory classification
Pumpkin seed oil One small RCT (AGA, oral) n=76 (2014) No Dietary supplement
PRP Multiple RCTs Systematic review data Some comparisons exist Off-label procedure

What the Evidence Actually Shows

Exosome therapy has a real biological rationale and early positive signals, but is currently an unregulated, unstandardized procedure with no large RCT behind it and active FDA concern about unapproved products. Stem cell and hair cloning approaches remain genuinely promising but experimentally stage-appropriate — not available treatments. Onion juice and pumpkin seed oil each have a single small study that cannot substitute for replication or a drug-benchmarked trial. None of these should displace treatments with established evidence.

Verdict & Practical Implications

Verdict: Claim Unsupported

The claims for these treatments as established or equivalent alternatives to approved drugs are unsupported. Evidence rating: 1–2/5 across the category — genuine science at various stages of development, none of it mature enough to constitute a treatment recommendation, and at least one category (commercial exosome injections) actively flagged by regulators.

The practical implication is a familiar one on this site: the absence of an easy cure does not mean these treatments are useless — it means they are early. Watch the literature. Do not pay clinic prices for unregulated procedures. Do not interpret a single unreplicated study, however striking the headline number, as an established treatment. And do not let the appeal of “natural” or “cutting-edge” language displace treatments that have actually been tested: minoxidil, finasteride, and — for those who qualify — the off-label options with real but less controlled evidence like spironolactone.

References & Further Reading